FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an antibody capable of binding to soluble protein of human extracellular domain CD39 (NTFDase 1) and inhibiting its ATF-phase activity (options), a kit for detection of protein CD39, containing the above-mentioned antibody, and a recombinant host cell producing the above-mentioned antibody. In one of implementations, the antibody contains three sections of HCDR containing amino acid sequences SEQ ID NO: 8-10 and three sections of LCDR containing amino acid sequences SEQ ID NO: 11-13.
EFFECT: invention expands the arsenal of means capable of binding to human CD39 and inhibiting its ATF-phase activity.
33 cl, 13 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD73 BLOCKING ANTIBODIES | 2020 |
|
RU2819204C2 |
| ANTI-CD39 ANTIBODIES, COMPOSITIONS CONTAINING ANTI-CD39 ANTIBODIES AND METHODS OF APPLICATION OF ANTI-CD39 ANTIBODIES | 2018 |
|
RU2795348C2 |
| ANTIBODIES THAT BIND TO CANCER CELLS AND PROVIDE TARGETED TRANSFER OF RADIONUCLIDES TO SAID CELLS | 2020 |
|
RU2833191C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| TREATMENT OF T-CELL LYMPHOMA | 2020 |
|
RU2835929C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
